DNA repair

Mar 11, 2020

IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities

Jan 23, 2020

Genetic Scanning System in Sperm May Control Rate of Human Evolution

Nov 06, 2019

Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor

Sep 30, 2019

Synthetic Lethality-based Drugs and Targets Market, 2030

Aug 16, 2019

With Over USD 4 Billion in Capital Investment, the Synthetic Lethality-based Drugs Market is Poised to Witness a Rapid Growth, Claims Roots Analysis

Mar 31, 2019

Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors

Jun 04, 2018

Caris Life Sciences Data Highlighted During ASCO Presentation Showing Cascading Effects of Tumor Repair Gene Mutations and Tumor Cell Phenotype

May 24, 2018

New Review of DNA Damage Response - An Emerging Target for Groundbreaking Cancer Therapies - touchONCOLOGY

Mar 08, 2018

Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases

Nov 29, 2017

NeoPhore Scientific Founders Publish Breakthrough Immuno-oncology Discoveries in Nature

Jun 05, 2017

Caris Life Sciences' Molecular Intelligence Platform Measures Prevalence of Oncogenic Homologous Recombination Pathway Mutations across 53,000 Tumors